Beam Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Net Income	-132.53	-289.09	-370.64	-195.87	-91.04	-117.33	-9.69
Depreciation & Amortization	20.01	14.15	7.45	4.74	3.5	0.65	0.01
Share-Based Compensation	98.65	84.32	43.57	15.38	7.03	7	0.2
Other Operating Activities	-135.33	213.15	253.35	78.74	-4.21	87.31	5.09
Operating Cash Flow	-149.2	22.53	-66.27	-95.74	-72	-20.3	-2.71
Capital Expenditures	-33.73	-48.95	-46.81	-16.36	-12.52	-13.12	-0.35
Acquisitions	0	0	0.62	0	0	0	0
Change in Investments	105.57	-412.39	-247.95	-83.77	-54.14	-0.3	0
Investing Cash Flow	71.84	-461.34	-294.14	-100.12	-66.66	-13.42	-0.35
Share Issuance / Repurchase	279.33	114.07	767.08	322.68	0.19	0.01	0
Debt Issued / Paid	-2.25	-2.29	-2.12	1.7	5.71	0	0
Other Financing Activities	-0.63	-0.19	-8.82	-2.06	35.38	179.72	4.98
Financing Cash Flow	276.45	111.59	756.14	322.32	41.28	179.73	4.98
Net Cash Flow	199.09	-327.22	395.73	126.46	-97.38	146.01	1.93
Free Cash Flow	-182.93	-26.42	-113.08	-112.1	-84.52	-33.42	-3.05
Free Cash Flow Margin	-48.43%	-43.37%	-218.11%	-467075.00%	-469561.11%	-	-
Free Cash Flow Per Share	-2.37	-0.38	-1.76	-2.40	-13.04	-11.55	-11.81

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).